BMY

Business profile & competitive position

Bristol-Myers Squibb Company is a single-segment biopharmaceutical company classified in the Healthcare sector, specifically the Drug Manufacturers - General industry. Its business spans the discovery, development, licensing, manufacturing, marketing, distribution, and sale of innovative medicines for serious diseases. The company’s therapeutic focus areas include oncology, hematology, immunology, cardiovascular, and neuroscience, and its products are sold worldwide primarily to wholesalers, distributors, specialty pharmacies, and to a lesser extent retailers, hospitals, clinics, government agencies, and directly to patients.

The financial footprint supports a research-driven model. Total revenues were $48.194 billion in 2025, essentially flat from $48.300 billion in 2024 and up from $45.006 billion in 2023. Research and development spending reached $10.0 billion in 2025, compared with $11.2 billion in 2024 and $9.3 billion in 2023, and the company reports more than 45 unique assets in development. Profitability metrics are strong: a 18.9% net margin and a 46.8% return on equity. Those figures point to meaningful operating leverage and efficient use of shareholder capital, which is consistent with an innovative-drug business that relies on patent-protected products and global commercial scale. At the same time, such a high ROE can also reflect financial leverage and capital structure choices, so it is best read as evidence of current profitability rather than proof of a permanent moat.

Financial posture

As of the current snapshot, Bristol-Myers Squibb had a market capitalization of $137.4 billion, a share price of $67.28, and traded at a 14.8 trailing P/E. The stock’s beta was 0.23, meaning it has historically exhibited far less market sensitivity than the broad equity average, a pattern frequently associated with large-cap pharmaceutical names and defensive positioning. The 50-day exponential moving average was $62.11, while the relative strength index stood at 63.4, sitting just below common overbought thresholds.

The combination of a sub-15 P/E, an 18.9% net margin, and a 46.8% ROE frames the company as a high-margin, equity-efficient operator relative to its market value. The low beta reinforces the idea that the equity behaves more like a defensive, income-oriented holding than a high-growth biotech name, although actual dividend yield is not included in the provided data.

Strategic priorities & outlook

Bristol-Myers Squibb’s most recent SEC 10-K filing outlines four near-term operational priorities: a focus on transformational medicines where the company has a competitive advantage; driving operational excellence throughout the organization; strategically allocating capital for long-term growth and shareholder returns; and driving commercial execution in key first-in-class and/or best-in-class marketed products. Those priorities emphasize a balanced playbook of pipeline innovation, cost discipline, capital deployment, and commercial execution rather than a single “big bet” strategy.

The 2025 business development record matches that framework. Significant activities included the acquisition of Orbital Therapeutics, a global strategic collaboration with BioNTech, and a global exclusive licensing agreement with Philochem. On the geographic front, 69% of 2025 revenues came from the United States, 29% from International markets, and 2% from Other. The revenue base is therefore heavily U.S.-weighted but retains meaningful offshore exposure that can influence reported growth through currency and pricing dynamics.

Macro & geopolitical exposure

As a global drug manufacturer, Bristol-Myers Squibb sits at the intersection of several macro and policy-driven forces. The most relevant exposures for the Drug Manufacturers - General industry include regulation by bodies such as the FDA and EMA, drug-pricing and reimbursement policies, patent expirations and generic competition, international trade policy, and foreign-exchange volatility. Tariffs or trade restrictions on active pharmaceutical ingredients and finished medicines can affect both cost structure and supply chain reliability, while reimbursement pressure in the U.S. and Europe can compress net realized pricing.

The company’s revenue mix—69% U.S. and 29% International in 2025—means currency translation can materially affect reported quarterly results even though the underlying prescription demand may be stable. Patent cliffs are another sector-wide consideration: loss of exclusivity on major franchises can open the door to generics or biosimilars and erode sales quickly. These macro variables are inherent to the industry classification and are worth tracking alongside the company-specific pipeline and earnings trajectory.

Recent developments

Recent news flow has been light on clinical announcements but active on institutional positioning and strategy commentary:

• On 2026-08-24, 247wallst.com published “JP Morgan Warns of Fall Sell-Off Potential: 5 Defensive Dividend Stocks to Buy,” which included Bristol-Myers Squibb among the defensive names. The headline alone reflects the stock’s low-beta profile and its place on a dividend-oriented watchlist, not a call to action.
• Also on 2026-08-24, defenseworld.net reported that Barbara Oil Co. acquired 42,000 shares of Bristol-Myers Squibb.
• On 2026-08-22, defenseworld.net noted that Blue Capital Inc. purchased 18,381 shares.
• On 2026-08-21, zacks.com ran “Can Eliquis Cushion Bristol Myers’ Legacy Portfolio Erosion?”—a framing question that highlights the market’s focus on whether newer or still-protected franchises can offset declines in older products.

None of these items alter the fundamental numbers, but they do illustrate how market participants are currently thinking about Bristol-Myers: as a large, defensive, cash-generating pharma name where pipeline and legacy-brand dynamics are closely watched.

Earnings behavior & post-earnings drift

Bristol-Myers Squibb has produced an unusually consistent earnings track record. Over the last 8 reported quarters, it has beaten the consensus estimate 8 out of 8 times, for a 100% beat rate, with an average earnings surprise of 17.2%. Despite that streak, the average 5-day price move after earnings across those quarters was -1.37%, classified as a “down” post-earnings drift. That divergence is a useful reminder that beating the estimate does not automatically translate into a sustained rally.

The four most recent quarters illustrate the point clearly:

• 2026-07-30: Actual EPS $2.04 vs. estimate $1.60 — a 27.5% surprise. The stock rose 0.69% the next day but slipped -1.09% over the following five sessions.
• 2026-04-30: Actual EPS $1.58 vs. estimate $1.42 — an 11.3% surprise. Shares fell -3.91% the next day and -7.16% over the next five.
• 2026-02-05: Actual EPS $1.26 vs. estimate $1.23 — a 2.4% surprise. The stock gained 4.15% the next day and added 0.57% over the following five.
• 2025-10-30: Actual EPS $1.63 vs. estimate $1.52 — a 7.2% surprise. The stock rose 0.99% the next day and 2.21% over the next five sessions.

Only two of the four most recent beats produced a positive five-day drift, while the July and April 2026 beats saw post-earnings selling. Traders often assume that a beat leads to follow-through, but Bristol-Myers’s history shows the market’s real expectation can already be priced in, with guidance, pipeline commentary, or sector sentiment driving the post-announcement price action. The next scheduled report is 2026-10-29 before the market open, with a consensus EPS estimate of $1.68.

For a deeper dive, readers should examine the full institutional verdict on Bristol-Myers Squibb, including consensus ratings, the distribution of analyst price targets, and detailed valuation and cash-flow models. The figures above provide a starting framework, not an investment recommendation.